BTG International Canada, a part of global specialist healthcare company BTG announced the commercial launch of DC Bead LUMI in Canada. The launch represents the first market commercialization of DC Bead LUMI in the world, with regulatory clearances and launches planned for additional markets worldwide.
BTG International Canada Inc. received Health Canada approval for DC Bead LUMI in August, 2016.
DC Bead LUMI is the first available radiopaque embolic drug-eluting bead that can be loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer or with irinotecan for the treatment of malignant colorectal cancer metastasized to the liver (mCRC ).
Drug-eluting beads are used in trans-arterial chemoembolization (TACE), which is a minimally invasive liver cancer treatment. Drug-eluting bead TACE combines the deliberate blocking of the blood supply to the tumour and delivery of a local, controlled, sustained dose of chemotherapy directly to the tumour.
DC Bead LUMI is a next generation development of DC Bead, the market leading drug-eluting embolic bead that has the potential to revolutionize the treatment of liver tumours.
The unique visibility of DC Bead LUMI helps optimize patient treatment by enabling real-time visible confirmation of bead location during and after the embolization procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.
Filed Under: Drug Discovery
